Department of Medical Oncology, University Campus Bio-Medico, Via Alvaro del Portillo, 200 00128 Rome, Italy.
Renal cell carcinoma represents approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. Many agents that target angiogenesis (e.g., sunitinib, sorafenib, bevacizumab and pazopanib) and mTOR-targeted therapy (e.g., temsirolimus and everolimus) have been approved as first-line agents. The choice of the most suitable treatment for advanced renal cell carcinoma depends on the definition of risk. In this article, we reviewed the scientific literature identifying predictive factors on the activity/efficacy of a specific therapy.
Written by:
Tonini G, Fratto ME, Imperatori M, Pantano F, Vincenzi B, Santini D. Are you the author?
Reference: Expert Rev Anticancer Ther. 2011 Jun;11(6):921-30.
doi: 10.1586/era.11.63
PubMed Abstract
PMID: 21707289
UroToday.com Renal Cancer Section
